Compare NWPX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWPX | RGNX |
|---|---|---|
| Founded | 1966 | 2008 |
| Country | United States | United States |
| Employees | 1318 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.3M | 761.9M |
| IPO Year | 1996 | 2015 |
| Metric | NWPX | RGNX |
|---|---|---|
| Price | $71.16 | $8.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $70.00 | $28.75 |
| AVG Volume (30 Days) | 79.6K | ★ 810.3K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.71 | ★ 18.08 |
| EPS | ★ 3.56 | N/A |
| Revenue | ★ $526,003,000.00 | $10,393,000.00 |
| Revenue This Year | $5.78 | $58.79 |
| Revenue Next Year | $4.48 | $29.74 |
| P/E Ratio | $20.58 | ★ N/A |
| Revenue Growth | 6.79 | ★ 126.48 |
| 52 Week Low | $36.99 | $5.04 |
| 52 Week High | $83.12 | $16.19 |
| Indicator | NWPX | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 40.83 |
| Support Level | $63.53 | $7.83 |
| Resistance Level | $77.43 | $9.28 |
| Average True Range (ATR) | 3.84 | 0.64 |
| MACD | -1.02 | 0.20 |
| Stochastic Oscillator | 5.64 | 23.57 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products, and operates in two segments, Water Transmission Systems (WTS), operating as the Northwest Pipe Company brand, and Precast Infrastructure and Engineered Systems (Precast), which includes the brands NWPX Geneva and NWPX Park. WTS manufactures large-diameter, high-pressure steel pipeline systems for use in water infrastructure applications, which are related to drinking water systems. Precast manufactures stormwater and wastewater technology products, high-quality precast and reinforced concrete products, including reinforced concrete pipe (RCP), manholes, box culverts, vaults, and catch basins, pump lift stations, oil water separators, biofiltration units, and other environmental and engineered solutions.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.